Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sexual Dysfunctions, Psychological 1Ovarian Neoplasms 1

Interventions

Specimen Handling 7pembrolizumab 6Cisplatin 6Magnetic Resonance Spectroscopy 4Human Papillomavirus DNA Tests 4Colposcopy 4Paclitaxel 3Nivolumab 3Fulvestrant 3Carboplatin 3Bevacizumab 3palbociclib 2lenvatinib 2Surveys and Questionnaires 2Radiotherapy, Intensity-Modulated 2Radiation Dose Hypofractionation 2Radiation 2Platinum 2Magnetic Resonance Imaging 2Gemcitabine 2Fluorodeoxyglucose F18 2Congresses as Topic 2Brachytherapy 2Biopsy 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 21,2-diaminocyclohexaneplatinum II citrate 2ulixertinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Bupropion × 30 days × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡